Quantcast

Latest Savient Pharmaceuticals Inc. Stories

2010-09-14 17:09:00

EAST BRUNSWICK, N.J., Sept. 14 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that the U.S. Food and Drug Administration (FDA) has approved KRYSTEXXA(TM) (pegloticase), a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy. Chronic gout that is refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and...

2010-08-03 19:40:00

EAST BRUNSWICK, N.J., Aug. 3 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today reported financial results for the three and six months ended June 30, 2010. The net loss for the second quarter of 2010 was $5.0 million, or $0.07 per basic and diluted share, on total revenues of $1.0 million, compared with a net loss of $54.8 million, or $0.92 per basic and diluted share on total revenues of $0.7 million for the second quarter of 2009. The net loss for the first...

2010-07-28 15:01:00

EAST BRUNSWICK, N.J., July 28 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced today that the company will release financial results for the second quarter 2010 following the close of the market on Tuesday, August 3, 2010. Paul Hamelin, President, and David Gionco, Group Vice President, Chief Financial Officer & Treasurer, will host an investment community conference call beginning at 9:00 a.m. Eastern Time on August 4, 2010 to discuss these results...

2010-05-05 15:49:00

EAST BRUNSWICK, N.J., May 5 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that its board of directors, with input from its financial advisors, has determined that a sale of Savient post-approval of KRYSTEXXA(TM) by the U.S. Food and Drug Administration (FDA) (assuming KRYSTEXXA is approved) would be the best way to realize the full commercial potential of KRYSTEXXA on a global basis and would be the optimal outcome for the Company's shareholders...

2010-04-30 15:05:00

EAST BRUNSWICK, N.J., April 30 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced today that the company will release financial results for the first quarter 2010 following the close of the market on Wednesday May 5, 2010. Paul Hamelin, R.Ph., President and David Gionco, Group Vice President and Chief Financial Officer, will host an investment community conference call beginning at 10:00 a.m. Eastern Time on May 6, 2010 to discuss these results and to answer...

2010-03-30 06:00:00

EAST BRUNSWICK, N.J., March 30 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced today that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of and accepted for review the March 15, 2010 resubmission of the Biologics License Application (BLA) for KRYSTEXXA(TM) (pegloticase), a treatment for chronic gout in patients refractory to conventional therapy. The FDA has deemed the resubmission a complete, class 2 response and has established...

2010-03-15 08:41:00

EAST BRUNSWICK, N.J., March 15 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that it has resubmitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for KRYSTEXXA(TM) (pegloticase) as a treatment for chronic gout in patients refractory to conventional therapy. Chronic gout that is refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are...

2010-02-25 18:04:00

EAST BRUNSWICK, N.J., Feb. 25 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today reported financial results for the three months and year ended December 31, 2009, ending the quarter with $108.2 million in cash and short-term investments, an increase of $29.6 million from December 31, 2008. In October 2009, the Company raised $61.4 million in cash, net of $4.3 million of offering costs from a secondary offering. For the fourth quarter of 2009, the Company had a...

2010-02-22 15:35:00

EAST BRUNSWICK, N.J., Feb. 22 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that Paul Hamelin, R.Ph., President of Savient will present at the Cowen and Company 30th Annual Health Care Conference on Monday, March 8, 2010 at 1:00 p.m. Eastern Time. The conference is being held at The Boston Marriott Copley Place. Individuals can access a live webcast of the presentation through the investor relations section of the Company's web site...

2010-02-08 15:35:00

EAST BRUNSWICK, N.J., Feb. 8 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced today that the company will release financial results for the fourth quarter and year-end 2009 following the close of the market on Thursday, February 25, 2010. Paul Hamelin, President and David Gionco, Group Vice President and Chief Financial Officer, will host an investment community conference call beginning at 10:00 a.m. Eastern Time on February 26, 2010 to discuss these...


Word of the Day
holluschickie
  • A 'bachelor seal'; a young male seal which is prevented from mating by its herd's older males (mated bulls defending their territory).
This comes from the Russian word for 'bachelors.'
Related